Special Packaging Delivers Inhaled Insulin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Special Packaging Delivers Inhaled Insulin


Pharmaceutical Technology


Injection molding and the assembly of in-house-produced and purchased parts occurs in a Class 100,000 cleanroom. The assembly process involves manual, semiautomatic, and fully automated operations. In fact, robots extract parts from the molding machines. Because most parts snap-fit together, adhesive usage is minimal. An automated laser-coding system etches alphanumeric codes on certain components to provide lot traceability. Pad printers apply logos, which not only identify the product but also help the patient position the inhaler properly for use. Quality control is stringent. Optical scanners monitor the assembly sequence, which includes a significant amount of testing to ensure the device will be functional and reliable for the duration of its recommended one-year usage.

To mitigate the risk of supply disruptions, Nektar and Pfizer wanted more than one contract manufacturer for the inhaler and selected a European counterpart for West's Tech Group. Bespak plc (Milton Keynes, UK, http://www.bespak.com/) manufactures the inhaler at a purpose-built facility in Milton Keynes, UK.

"Although they would ordinarily be considered a competitor, we partnered on this project," says Treadaway. "They have the same molding machines, the same automation, the same molds. In addition, manufacturing processes were developed to ensure interchangeability plant-to-plant," he adds. In addition, each facility follows the same standards and complies with FDA and EC regulatory requirements to ensure each inhaler is acceptable for shipment anywhere.

In addition to filling the blisters, Pfizer's Terre Haute plant performs final kitting and distribution tasks. Patient packs come in a variety of configurations, including a combination pack that includes both 1- and 3-mg doses. An Exubera "CareKit" consists of one inhaler, a replacement chamber, and two Exubera release units that are individually packaged in sealed, thermoformed trays. The latter items also are sold separately.

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 Morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here